The NORwegian Atrial Fibrillation Self-SCREENing

Last updated: July 26, 2024
Sponsor: Oslo University Hospital
Overall Status: Active - Recruiting

Phase

N/A

Condition

Arrhythmia

Chest Pain

Dysrhythmia

Treatment

Long-term continuous ECG monitoring

Clinical Study ID

NCT05914883
477781
  • Ages > 65
  • All Genders
  • Accepts Healthy Volunteers

Study Summary

Atrial fibrillation (AF) is common, increases the risk of mortality, stroke and heart failure, and portending significant burden to patients, societal health and health economy. One of three AF cases are undiagnosed. Several methods for detection of AF exist, but most of them have major limitations and are associated with resource-demanding diagnostic workup in the speciality health care services.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • Age ≥65 years and minimum one other risk factor for stroke according to theCHA2DS2-VASc risk score: Age ≥75 years, Diabetes, Heart failure, Hypertension,Previous stroke/TIA and/or Vascular disease

  • Informed consent for participation

Exclusion

Exclusion Criteria:

  • History of AF (self-reported)

  • Use of anticoagulation therapy

  • Pacemaker/CRT device

  • No smart phone

Study Design

Total Participants: 35000
Treatment Group(s): 1
Primary Treatment: Long-term continuous ECG monitoring
Phase:
Study Start date:
September 01, 2023
Estimated Completion Date:
December 31, 2029

Study Description

This randomized clinical trial will evaluate whether self-screening for AF with the ECG247 patch monitor will reduce AF-related morbidity.

Connect with a study center

  • Sorlandet Hospital

    Arendal,
    Norway

    Site Not Available

  • Oslo Unvirsity Hospital

    Oslo,
    Norway

    Active - Recruiting

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.